# Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

> **NCT06962137** · PHASE2 · RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 100 (estimated)

## Conditions studied

- Gastric Cancer Adenocarcinoma Metastatic
- Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** zolbetuximab
- **OTHER:** Retrospective cohort, no intervention

## Key facts

- **NCT ID:** NCT06962137
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-11
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-08-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962137, "Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06962137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*